New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GDOT;ELN;MRK;CTRP;DELL;NFLX;MAT;MCK;VVUS;ALKS;ADNC;LTM;TSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 9, 2015
10:05 EDTCTRPCtrip.com participates in a breakfast meeting with Piper Jaffray
Subscribe for More Information
09:25 EDTMRKPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
April 8, 2015
14:57 EDTNFLXNetflix April volatility into Q1 and outlook
Netflix April weekly call option implied volatility is at 26, April is at 78, May is at 49; compared to its 26-week average of 36 according to Track Data, suggesting larger price movement into the expected release of Q1 results on April 15.
14:50 EDTNFLXGoogle plans ad-free YouTube subscription service, Bloomberg says
Google (GOOG) is planning to launch a YouTube subscription service as early as this year, reports Bloomberg, citing a person with knowledge of the matter and a YouTube letter sent to certain content creators on the site. The new paid version of the site will be free of ads and may include a type of offline access to YouTube. Bloomberg notes that the move will put the streaming site into closer competition with Netflix (NFLX), Time Warner's (TWX) HBO Now, and similar paid streaming services. Reference Link
09:35 EDTNFLXActive equity options trading on open
Subscribe for More Information
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
April 7, 2015
15:08 EDTNFLXArrested Development producer says 17 new episodes to be produced
Subscribe for More Information
10:05 EDTCTRPOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Carnival (CCL) upgraded to Outperform from Market Perform at Wells Fargo... Crown Castle (CCI) upgraded to Buy from Hold at Evercore ISI... Ctrip.com (CTRP) upgraded to Overweight from Neutral at Piper Jaffray... Demandware (DWRE) upgraded to Conviction Buy from Buy at Goldman... FirstEnergy (FE) upgraded at BofA/Merrill... Frontier Communications (FTR) upgraded to Neutral from Underperform at DA Davidson... JPMorgan (JPM) upgraded to Outperform from Market Perform at Bernstein... Pattern Energy (PEGI) upgraded to Outperform from Market Perform at Raymond James... Ralph Lauren (RL) upgraded to Buy from Outperform at CLSA... ResMed (RMD) upgraded to Outperform from Neutral at Credit Suisse... Ryanair (RYAAY) upgraded to Overweight from Neutral at JPMorgan... Splunk (SPLK) upgraded to Overweight from Neutral at Piper Jaffray... Total (TOT) upgraded at RBC Capital... Verifone (PAY) upgraded to Buy from Hold at Stifel... XL Group (XL) upgraded to Buy from Neutral at UBS.
09:35 EDTNFLXActive equity options trading on open
Subscribe for More Information
07:29 EDTMATMKM Partners lowers Mattel estimates on FX and port issues
Subscribe for More Information
07:14 EDTMRKEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
05:36 EDTCTRPCtrip.com upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Michael Olson upgraded Ctrip.com to Overweight saying the company is making the right investments to take further share of the Chinese travel market. Olson believes Ctrip.com's is positioned for margin expansion and that long-term investors should own the stock. He raised his price target for the name to $90 from $54. Shares of the hotel accommodations and airline tickets consolidator closed Monday at $61.17.
April 6, 2015
16:00 EDTNFLXOptions Update; April 6, 2015
iPath S&P 500 VIX Short-Term Futures down 51c to 24.53. Option volume leaders: AAPL TSLA VZ TWTR BIDU RIG NFLX AMZN KO PBR according to Track Data.
11:23 EDTMATMattel moves off session highs, levels to watch
Subscribe for More Information
10:06 EDTALKSAlkermes shares unlikely to move much on ALKS 3831 data, says UBS
Subscribe for More Information
10:02 EDTMATOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:03 EDTALKSAlkermes says ALKS 3831 met primary, secondary endpoints in Phase 2 study
Subscribe for More Information
06:54 EDTMATMattel upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
April 5, 2015
16:29 EDTNFLXNetflix's 'House of Cards' to return for fourth season
Netflix's official twitter account for "House of Cards" tweeted on Thursday the following: "I will leave a legacy." Along with the tweet was a picture with an upside down American flag that said, "Season 4 coming in 2016." Reference Link
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use